Preclinical Pipeline

Addex has built over the years a pipeline of programs that have reached stages from early Hit-to-Lead to Late Lead Optimisation. All our programs are based on allosteric modulation, either positive or negative, and represent unique opportunities for development of novel therapies for diseases with high unmet medical need. We are currently advancing these programs through collaborations with academic labs, with the support from funding from Innosuisse (formerly the Swiss Commission for Technology and Innovation) and The Michael J Fox Foundation.

New Pre Clinical.JPG